BioequivalencePhase 1NCT04768985
Study to Assess the Bioequivalence of Acalabrutinib Tablet and Acalabrutinib Capsule
A Phase 1 study testing Treatment A: Acalabrutinib tablet and Treatment B: Acalabrutinib capsule in people with Bioequivalence, run by AstraZeneca at 3 sites in United States.
Trial summary
This study is a multicenter, Phase I, open-label, randomized, 2-sequence, 2-treatment, 2-period, crossover, bioequivalence study with single doses of acalabrutinib administered orally in healthy participants. Read more about this study
- Who is it for?
- Ages 18 to 55 yearsHealthy volunteers can take part
- Conditions the study is for
- Bioequivalence
- What is being tested?
- Treatment A: Acalabrutinib tablet and Treatment B: Acalabrutinib capsule
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 66 participants
- Where
- 3 sitesUnited States
- Study dates
- 25 Feb 2021to 10 May 2021
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 55 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Females must have a negative pregnancy test at Screening and on admission to the study center, must not be lactating, and must be of non-childbearing potential, confirmed at Screening, by fulfilling protocol defined criteria
- Have a body mass index between 18.5 and 30 kg/m^2 inclusive and weigh at least 50 kg and no more than 100 kg inclusive, at Screening
- Non-smokers and those participants who have not smoked (including e cigarettes) or used nicotine products (cigarettes, pipes, cigars, chewing tobacco, nicotine patch, or any other nicotine containing products) within the 90 days prior to Screening
- Calculated creatinine clearance (CrCl) ≥ 90 mL/min as determined by Cockcroft-Gault method (using actual body weight)
- Males:
- CrCl = Weight (kg) × (140 - Age)/72 × serum creatinine (mg/dL) in mL/min
- Females:
- CrCl = Weight (kg) × (140 - Age) × 0.85/72 × serum creatinine (mg/dL) in (mL/min)
Who cannot join
- History or presence of any clinically significant disease (including active coronavirus disease 2019 [COVID-19] infection) or disorder
- History or presence of gastrointestinal, hepatic, or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs
- Any clinically significant illness, medical/surgical procedure, or trauma within 30 days of the first administration of study drug
- Any clinically significant abnormalities in hematology, coagulation, clinical chemistry, or urinalysis results, at Screening and prior to first dose, as judged by the Investigator and defined as:
- Hemoglobin less than lower limit of normal (ii) Absolute neutrophils less than lower limit of normal (iii) Platelets less than lower limit of normal (iv) Serum alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase or serum bilirubin (total bilirubin and direct bilirubin) > upper limit of normal
- Any clinically significant abnormal findings in vital signs at Screening or on Day 1 (eg, systolic BP < 90 mmHg or > 140 mmHg; diastolic BP < 50 mmHg or > 90 mmHg; pulse < 45 or > 90 bpm)
Show all 20Show fewer
- Any clinically significant abnormalities on standard 12-lead ECG at Screening or on Day 1
- Any positive result for HBsAg, hepatitis C antibody, and HIV testing, at Screening
- Has received a new chemical entity (defined as a compound which has not been approved for marketing) within 90 days of the first administration of study drug in this study. The period of exclusion begins 90 days after the final dose or 30 days after the last visit whichever is the longest
- History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, or history of hypersensitivity to drugs with a similar chemical structure or class to acalabrutinib
- Positive screen for drugs of abuse or cotinine and alcohol, at Screening and on admission to the study center
- Treatment with prescription or non-prescription drugs or other products known to be strong CYP3A, P-gp, or breast cancer resistance protein (BCRP) inhibitors or substrates of BCRP or MATE1 (within 14 days before first administration of study drug or longer if the medication has a long half life) and strong CYP3A inducers (within 28 days before first administration of study drug or longer if the medication has a long half life)
- Use of any prescribed or non prescribed medication including antacids, analgesics (other than paracetamol/acetaminophen), herbal remedies, megadose vitamins (intake of 20 to 600 times the recommended daily dose), and minerals during the 14 days prior to the first administration of study drug or longer if the medication has a long half life
- Excessive intake of caffeine-containing drinks or food (eg, coffee, tea, chocolate) as judged by the Investigator
- Inability to swallow acalabrutinib tablets or acalabrutinib capsules
- Evidence of ongoing systemic bacterial, fungal, or viral infection (including upper respiratory tract infections)
- Participant has a positive test result for severe acute respiratory syndrome coronavirus 2 reverse transcriptase polymerase chain reaction before randomization
- Participant has clinical signs and symptoms consistent with COVID-19, eg, fever, dry cough, dyspnea, sore throat, fatigue, or confirmed infection by appropriate laboratory test within the last 4 weeks prior to Screening or on admission
- History of severe COVID-19 (hospitalization, extracorporeal membrane oxygenation, mechanically ventilated)
- Participants who are regularly exposed to COVID-19 as part of their daily life (eg, health care professionals working in COVID-19 wards or at emergency departments)
Trial locations and contacts
3 sites in 1 country.
United States3 sites
Research Site
Brooklyn, Maryland, 21225
Research Site
Glendale, California, 91206
Research Site
Salt Lake City, Utah, 84107
About this study
Official title: A Phase I, Open-Label, Randomized, 2-Treatment, 2-Period, Crossover Study in Healthy Subjects to Assess the Bioequivalence of Acalabrutinib Tablet and Acalabrutinib Capsule
This study is a multicenter, Phase I, open-label, randomized, 2-sequence, 2-treatment, 2-period, crossover, bioequivalence study with single doses of acalabrutinib administered orally in healthy participants. The study is designed to demonstrate the bioequivalence of acalabrutinib tablet (Treatment A) compared with marketed acalabrutinib capsule (Treatment B) in the fasted state.
Read the detailed description
Eligible healthy participants will be randomized to receive either treatment sequence 1 (AB) or treatment sequence 2 (BA), as follows:
- Treatment A: Acalabrutinib tablet, 100 mg, fasted state
- Treatment B: Acalabrutinib capsule, 100 mg, fasted state
Participants will receive fixed single doses of acalabrutinib on 2 occasions, under fasted conditions.
The study will comprise:
- Visit 1: A screening period of up to 28 days before first dosing.
- Visit 2: Two treatment periods:
- Participants will be admitted to the study center on Day -2 of Treatment Period 1 to confirm eligibility before first dosing. Eligibility criteria will be reconfirmed on Day -1 of each treatment period.
- On Day 1 of Treatment Periods 1 and 2, participants will be administered the assigned treatment (A or B) as randomized, followed by a protocol defined washout period between Treatment Periods 1 and 2.
- Visit 3: A Follow-up Visit/Early Termination Visit at 7 to 10 days after last administration of study drug.
Each participant will be involved in the study for approximately 6 weeks.
- Conditions
- Bioequivalence
- Being tested
- Treatment A: Acalabrutinib tablet, Treatment B: Acalabrutinib capsule
- Keywords
- Pharmacokinetics, Healthy participants, Bruton tyrosine kinase, Acalabrutinib
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Treatment A: Acalabrutinib tabletDrug
Also called CALQUENCE
Participants will receive fixed single doses of acalabrutinib tablet in 2 treatment periods, under fasted conditions.
Treatment B: Acalabrutinib capsuleDrug
Also called CALQUENCE
Participants will receive fixed single doses of acalabrutinib capsule in 2 treatment periods, under fasted conditions.
| Study group | Role | What they receive |
|---|---|---|
| Treatment sequence 1: Treatment AB | Experimental | Participants will be randomized to receive one of the two different treatment sequences. In each treatment sequence participant will receive fixed single doses of 100 mg acalabrutinib orally (Treatment A; Treatment B) in 2 treatment periods, under fasted conditions. Treatment A will include acalabrutinib tablet and Treatment B will include acalabrutinib capsule. Receives: Drug: Treatment A: Acalabrutinib tablet; Drug: Treatment B: Acalabrutinib capsule |
| Treament sequence 2: Treatment BA | Experimental | Participants will be randomized to receive one of the two different treatment sequences. In each treatment sequence participant will receive fixed single doses of 100 mg acalabrutinib orally (Treatment B; Treatment A) in 2 treatment periods, under fasted conditions. Treatment A will include acalabrutinib tablet and Treatment B will include acalabrutinib capsule. Receives: Drug: Treatment A: Acalabrutinib tablet; Drug: Treatment B: Acalabrutinib capsule |
What is being measured
The primary outcome is the main question the study is designed to answer.
Area under plasma concentration time curve from zero to infinity (AUCinf) of Acalabrutinib
To compare the AUCinf of acalabrutinib capsule with the tablet.
Measured: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, and 48 hours post-dose
Area under the plasma concentration time curve from zero to the last quantifiable concentration (AUClast) of Acalabrutinib
To compare the AUClast of acalabrutinib capsule with the tablet.
Measured: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, and 48 hours post-dose
Maximum observed plasma (peak) drug concentration (Cmax) of Acalabrutinib
To compare the Cmax of acalabrutinib capsule with the tablet
Measured: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, and 48 hours post-dose
Secondary outcomes (10)
Area under plasma concentration time curve from zero to infinity (AUCinf) of ACP-5862
To compare the AUCinf of acalabrutinib capsule with the tablet.
Measured: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, and 48 hours post-dose
Area under the plasma concentration time curve from zero to the last quantifiable concentration (AUClast) of ACP-5862
To compare the AUClast of acalabrutinib capsule with the tablet.
Measured: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, and 48 hours post-dose
Maximum observed plasma (peak) drug concentration (Cmax) of ACP-5862
To compare the Cmax of acalabrutinib capsule with the tablet.
Measured: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, and 48 hours post-dose
Time to reach peak or maximum concentration (tmax) following drug administration for acalabrutinib and ACP-5862
To compare the tmax of acalabrutinib capsule with the acalabrutinib tablet.
Measured: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, and 48 hours post-dose
Half life associated with terminal slope (λz) of a semi logarithmic concentration time curve (t½λz) for acalabrutinib and ACP-5862
To compare the t½λz of acalabrutinib capsule with the acalabrutinib tablet.
Measured: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, and 48 hours post-dose
Mean residence time of the unchanged drug in the systemic circulation from zero to infinity (MRT) for acalabrutinib and ACP-5862
To compare the MRT of acalabrutinib capsule with the acalabrutinib tablet.
Measured: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, and 48 hours post-dose
Terminal rate constant, estimated by log linear least squares regression of the terminal part of the concentration time curve (λz) for acalabrutinib and ACP-5862
To compare the λz of acalabrutinib capsule with the acalabrutinib tablet.
Measured: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, and 48 hours post-dose
Metabolite (ACP-5862) to parent (acalabrutinib) ratio based on AUCinf and/or AUClast (M:P[AUC])
To compare the M:P[AUC] of acalabrutinib capsule with the tablet.
Measured: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, and 48 hours post-dose
Metabolite (ACP-5862) to parent (acalabrutinib) ratio based on Cmax (M:P [Cmax])
To compare the M:P[Cmax] of acalabrutinib capsule with the tablet.
Measured: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, and 48 hours post-dose
Number of participants with adverse events and serious adverse events
Comparison of the safety and tolerability of single doses of acalabrutinib capsule with the tablet.
Measured: From screening day (Day -28) until Follow-up/end of treatment visit (at 7 to 10 days after last study drug administration)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Feb 2021
- Study start25 Feb 2021
- Primary completion10 May 2021
- Study completion10 May 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for BioequivalenceStudies of the same condition, open and under way.
- More trials run by AstraZenecaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Enrolment
- 66 participants (actual)
Sponsor and investigators
- Lead sponsor
- AstraZeneca
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Ronald Goldwater, MD, Principal investigator, Parexel Early Phase Clinical Unit Baltimore Harbor Hospital 3001 South Hanover St. Baltimore, MD 21225 USA
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04768985
- Sponsor's protocol ID
- D8223C00013
- Status last verified
- Mar 2022
- First submitted
- 22 Feb 2021
- Last updated
- 8 Jul 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Study at a glance
From the registry record, last updated by the sponsor on 8 Jul 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase I, Open-Label, Randomized, 2-Treatment, 2-Period, Crossover Study in Healthy Subjects to Assess the Bioequivalence of Acalabrutinib Tablet and Acalabrutinib Capsule
- ClinicalTrials.gov ID
- NCT04768985
- Acronym / sponsor ID
- D8223C00013
- Conditions
- Bioequivalence
- Keywords
- Pharmacokinetics, Healthy participants, Bruton tyrosine kinase, Acalabrutinib
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 66 participants (actual)
- Lead sponsor
- AstraZenecaIndustry (pharma, biotech, devices)
- Study start
- 25 Feb 2021 (actual)
- Primary completion
- 10 May 2021 (actual)
- Study completion
- 10 May 2021 (actual)
- First posted
- 24 Feb 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is a multicenter, Phase I, open-label, randomized, 2-sequence, 2-treatment, 2-period, crossover, bioequivalence study with single doses of acalabrutinib administered orally in healthy participants. The study is designed to demonstrate the bioequivalence of acalabrutinib tablet (Treatment A) compared with marketed acalabrutinib capsule (Treatment B) in the fasted state.
Detailed description
Eligible healthy participants will be randomized to receive either treatment sequence 1 (AB) or treatment sequence 2 (BA), as follows:
- Treatment A: Acalabrutinib tablet, 100 mg, fasted state
- Treatment B: Acalabrutinib capsule, 100 mg, fasted state
Participants will receive fixed single doses of acalabrutinib on 2 occasions, under fasted conditions.
The study will comprise:
- Visit 1: A screening period of up to 28 days before first dosing.
- Visit 2: Two treatment periods:
- Participants will be admitted to the study center on Day -2 of Treatment Period 1 to confirm eligibility before first dosing. Eligibility criteria will be reconfirmed on Day -1 of each treatment period.
- On Day 1 of Treatment Periods 1 and 2, participants will be administered the assigned treatment (A or B) as randomized, followed by a protocol defined washout period between Treatment Periods 1 and 2.
- Visit 3: A Follow-up Visit/Early Termination Visit at 7 to 10 days after last administration of study drug.
Each participant will be involved in the study for approximately 6 weeks.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Treatment sequence 1: Treatment AB | Experimental | Drug: Treatment A: Acalabrutinib tablet, Drug: Treatment B: Acalabrutinib capsuleParticipants will be randomized to receive one of the two different treatment sequences. In each treatment sequence participant will receive fixed single doses of 100 mg acalabrutinib orally (Treatment A; Treatment B) in 2 treatment periods, under fasted conditions. Treatment A will include acalabrutinib tablet and Treatment B will include acalabrutinib capsule. |
| Treament sequence 2: Treatment BA | Experimental | Drug: Treatment A: Acalabrutinib tablet, Drug: Treatment B: Acalabrutinib capsuleParticipants will be randomized to receive one of the two different treatment sequences. In each treatment sequence participant will receive fixed single doses of 100 mg acalabrutinib orally (Treatment B; Treatment A) in 2 treatment periods, under fasted conditions. Treatment A will include acalabrutinib tablet and Treatment B will include acalabrutinib capsule. |
Who may qualify
- Ages
- 18 to 55 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (8 listed)
- Females must have a negative pregnancy test at Screening and on admission to the study center, must not be lactating, and must be of non-childbearing potential, confirmed at Screening, by fulfilling protocol defined criteria
- Have a body mass index between 18.5 and 30 kg/m^2 inclusive and weigh at least 50 kg and no more than 100 kg inclusive, at Screening
- Non-smokers and those participants who have not smoked (including e cigarettes) or used nicotine products (cigarettes, pipes, cigars, chewing tobacco, nicotine patch, or any other nicotine containing products) within the 90 days prior to Screening
- Calculated creatinine clearance (CrCl) ≥ 90 mL/min as determined by Cockcroft-Gault method (using actual body weight)
- CrCl = Weight (kg) × (140 - Age)/72 × serum creatinine (mg/dL) in mL/min
Key exclusion criteria (20 listed)
- History or presence of any clinically significant disease (including active coronavirus disease 2019 [COVID-19] infection) or disorder
- History or presence of gastrointestinal, hepatic, or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs
- Any clinically significant illness, medical/surgical procedure, or trauma within 30 days of the first administration of study drug
- Any clinically significant abnormalities in hematology, coagulation, clinical chemistry, or urinalysis results, at Screening and prior to first dose, as judged by the Investigator and defined as:
- Any clinically significant abnormal findings in vital signs at Screening or on Day 1 (eg, systolic BP < 90 mmHg or > 140 mmHg; diastolic BP < 50 mmHg or > 90 mmHg; pulse < 45 or > 90 bpm)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Treatment A: Acalabrutinib tabletAlso: CALQUENCEParticipants will receive fixed single doses of acalabrutinib tablet in 2 treatment periods, under fasted conditions. | Drug | Treament sequence 2: Treatment BA, Treatment sequence 1: Treatment AB |
| Treatment B: Acalabrutinib capsuleAlso: CALQUENCEParticipants will receive fixed single doses of acalabrutinib capsule in 2 treatment periods, under fasted conditions. | Drug | Treament sequence 2: Treatment BA, Treatment sequence 1: Treatment AB |
Primary outcome
Area under plasma concentration time curve from zero to infinity (AUCinf) of Acalabrutinib
Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, and 48 hours post-dose
To compare the AUCinf of acalabrutinib capsule with the tablet.
Area under the plasma concentration time curve from zero to the last quantifiable concentration (AUClast) of Acalabrutinib
Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, and 48 hours post-dose
To compare the AUClast of acalabrutinib capsule with the tablet.
Maximum observed plasma (peak) drug concentration (Cmax) of Acalabrutinib
Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, and 48 hours post-dose
To compare the Cmax of acalabrutinib capsule with the tablet
10 secondary outcomes
Area under plasma concentration time curve from zero to infinity (AUCinf) of ACP-5862
Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, and 48 hours post-dose
Area under the plasma concentration time curve from zero to the last quantifiable concentration (AUClast) of ACP-5862
Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, and 48 hours post-dose
Maximum observed plasma (peak) drug concentration (Cmax) of ACP-5862
Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, and 48 hours post-dose
Time to reach peak or maximum concentration (tmax) following drug administration for acalabrutinib and ACP-5862
Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, and 48 hours post-dose
Half life associated with terminal slope (λz) of a semi logarithmic concentration time curve (t½λz) for acalabrutinib and ACP-5862
Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, and 48 hours post-dose
Mean residence time of the unchanged drug in the systemic circulation from zero to infinity (MRT) for acalabrutinib and ACP-5862
Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, and 48 hours post-dose
Terminal rate constant, estimated by log linear least squares regression of the terminal part of the concentration time curve (λz) for acalabrutinib and ACP-5862
Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, and 48 hours post-dose
Metabolite (ACP-5862) to parent (acalabrutinib) ratio based on AUCinf and/or AUClast (M:P[AUC])
Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, and 48 hours post-dose
Metabolite (ACP-5862) to parent (acalabrutinib) ratio based on Cmax (M:P [Cmax])
Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, and 48 hours post-dose
Number of participants with adverse events and serious adverse events
Time frame: From screening day (Day -28) until Follow-up/end of treatment visit (at 7 to 10 days after last study drug administration)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Jul 2022.
- Results of this clinical trial are available on www.astrazenecaclinicaltrials.comLink provided by the sponsor.
- Individual participant dataSharing planned: Yes. Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Related trials for Bioequivalence
Not yet recruitingPhase 1
A Study of Imlunestrant (LY3484356) in Healthy Female Participants
Healthy
RecruitingPhase 1
A Randomized, Double-Blind, Positive-Controlled, Parallel Pharmacokinetic Phase I Clinical Study of Cetuximab Injection Versus Erbitux in Healthy Male Subjects
Cetuximab, Bioequivalence
RecruitingPhase 1
Bioequivalence Study Between YHP2508B and YHR2602 in Healthy Subjects
Healthy Subjects (HS)
Active, not recruitingPhase 1
A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer
Prostatic Neoplasms
RecruitingPhase 1
Bioequivalence Study Between YHP2508A and YHR2601 in Healthy Subjects
Healthy Subjects (HS)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Ronald Goldwater, MD principal investigator
Parexel Early Phase Clinical Unit Baltimore Harbor Hospital 3001 South Hanover St. Baltimore, MD 21225 USA
3 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing Treatment A: Acalabrutinib tablet and Treatment B: Acalabrutinib capsule in people with Bioequivalence, run by AstraZeneca at 3 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 20 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 8 Jul 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Area under plasma concentration time curve from zero to infinity (AUCinf) of Acalabrutinib (time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, and 48 hours post-dose). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Jul 2022.